On the stock market since 2022, it operates in the world of health and science. It has 78 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Average growth of 7% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 19% below its peak. The market has trimmed its expectations for the company.
Sales run at $18.2M a year. A small number, but proof the product has real buyers.
A loss of $360.5M against $18.2M in annual sales.
The stock sits at $0.04. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, MSPRZ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MSPRZ is a high-risk stock — not yet profitable, and its future rides on its product catching on.